preloader-logo

Venture Capital

A differentiated approach to healthcare venture

Since 2008, the NEMO (New Emerging Medical Opportunities) family of late-stage venture capital funds has invested in innovative biotech and medtech companies across North America and Europe. In 2023, we launched the Fonds Medtech Ventures (FMV), which focuses on Canadian medtech companies. We use funds and the operational expertise of our entire team to help our companies bring novel therapeutics and medical devices to patients around the world. Our investment philosophy is grounded in the belief that financial performance can go hand in hand with driving lasting benefits for society through improved health and well-being.

Investment Strategy

We believe that the best investment opportunity should win the day. We look for and back the most innovative and high-potential companies across North America and Europe and in virtually all areas of biotechnology and medical device innovation.

Fonds Medtech Ventures (FMV)
Geography: Canada
Sector: Medtech
Stage: Series A or first institutional round

The FMV focuses on early-stage Canadian medical technology companies. The strategy consists in identifying therapeutic or diagnostic solutions with the potential to be disruptive on a global scale. The Fund finances and plays an active role in executing a development plan that maximises the technologies’ full potential. Sectoral acts as a lead for the majority of initial investments and seeks representation at the board level. The FMV portfolio aims to generate greater than 4x returns over 6-8 years from initial investment.

Risks and limitations of using targeted performance are available upon request.

Geography: North America and Europe
Sector: Biotechnologies and Medical Technologies
Stage: Series B or later

The NEMO strategy focuses on investing in clinical stage companies with a high potential for risk-adjusted financial return and real-world patient impact. Sectoral leads or co-leads the majority of initial investments and holds a director seat on the board of most of its NEMO portfolio companies. With a driving belief that value creation and capital flows should move at the speed of modern science, the NEMO portfolio aims to generate 3-5x returns over 2-4 years from initial investment.

Risks and limitations of using targeted performance are available upon request.

Team

Led by three partners, the venture team includes a diverse set of experienced healthcare investors, expert investment professionals, startup entrepreneurs and company builders, and successful industry veterans. All of our team members have advanced degrees in science, medicine, engineering, or business, with many holding a CFA designation.

Our team has sourced, built, bought, and sold healthcare companies at all stages of development, and we bring our rigorous investment discipline and operational experience to bear on every investment decision and portfolio company.

Investment team Industry partners
>

Portfolio

Current Full and Partial Exits

News

See more in our media center